Beur schreef op 13 januari 2020 15:09:
Amicus Therapeutics provides FY 2020 strategic and financial outlook
Jan. 13, 2020 8:55 AM ET|About: Amicus Therapeutics, Inc. (FOLD)|By: Mamta Mayani, SA News Editor
- For FY 2020, the Company anticipates total Galafold* revenue of $250M to $260M.
- To complete Pompe Phase 3 PROPEL study, enroll pediatric studies and advance manufacturing to support 2021 BLA and MAA, data expected H1 2021.
- Progress Pompe gene therapy towards IND and disclose up to two additional IND candidates.
* Galafold is hun vorig jaar goedgekeurde medicijn voor Fabry